Analysts Set Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Target Price at $15.00

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) have been assigned an average recommendation of “Moderate Buy” from the six brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $15.00.

Several research analysts have weighed in on the stock. Capital One Financial downgraded shares of Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $12.00 to $4.00 in a research report on Thursday, August 8th. StockNews.com upgraded Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, July 16th. Wells Fargo & Company cut their price target on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating for the company in a report on Friday, August 9th. Finally, Craig Hallum decreased their price objective on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, August 9th.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other news, insider Minardo John sold 9,910 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $4.27, for a total transaction of $42,315.70. Following the completion of the transaction, the insider now directly owns 284,661 shares of the company’s stock, valued at approximately $1,215,502.47. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, Director Julie Mchugh sold 22,766 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $6.29, for a total transaction of $143,198.14. Following the completion of the sale, the director now directly owns 139,528 shares in the company, valued at $877,631.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Minardo John sold 9,910 shares of the firm’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $4.27, for a total transaction of $42,315.70. Following the completion of the transaction, the insider now directly owns 284,661 shares in the company, valued at $1,215,502.47. The disclosure for this sale can be found here. Over the last three months, insiders have sold 77,102 shares of company stock valued at $468,063. 12.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Signaturefd LLC increased its position in shares of Ironwood Pharmaceuticals by 61.4% during the fourth quarter. Signaturefd LLC now owns 2,160 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 822 shares during the period. CWM LLC increased its holdings in Ironwood Pharmaceuticals by 55.1% during the 2nd quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 2,345 shares during the period. PNC Financial Services Group Inc. raised its position in Ironwood Pharmaceuticals by 152.2% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,383 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 2,645 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Ironwood Pharmaceuticals by 344.1% in the 2nd quarter. GAMMA Investing LLC now owns 10,526 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 8,156 shares during the period. Finally, First Dallas Securities Inc. acquired a new position in shares of Ironwood Pharmaceuticals during the second quarter worth about $73,000.

Ironwood Pharmaceuticals Stock Performance

NASDAQ:IRWD opened at $5.06 on Thursday. The firm has a market cap of $808.28 million, a P/E ratio of -0.75 and a beta of 0.52. Ironwood Pharmaceuticals has a fifty-two week low of $3.79 and a fifty-two week high of $15.70. The firm has a 50-day simple moving average of $5.89 and a two-hundred day simple moving average of $7.50.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.